Mutated DNA Restored to Normal in Gene Therapy Advance [The New York Times]
Verve Therapeutics, Inc. (NASDAQ: VERV) had its price target lowered by analysts at Royal Bank of Canada from $17.00 to $15.00. They now have an "outperform" rating on the stock.
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics, Inc. (NASDAQ: VERV) had its price target raised by analysts at HC Wainwright from $14.00 to $15.00. They now have a "buy" rating on the stock.
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]